FTC seeks more information to review Bristol-Celgene's $74 billion planned merger [Reuters (UK)]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Reuters
FTC seeks more information to review Bristol-Celgene's $74 billion planned merger | Reuters 2 Min Read (Reuters) - The U.S. Federal Trade Commission has sought additional information and documents from Bristol-Myers Squibb Co and Celgene Corp in connection with its review of their planned merger, Bristol-Myers said on Tuesday. "The parties understand that the FTC's review is focussed on marketed and pipeline products for the treatment of psoriasis," Bristol-Myers said here in a filing. Celgene’s psoriasis drug Otezla brought $448 million (339 million pounds) in sales in the quarter ended Dec. 31. Bristol-Myers is also developing a treatment for the condition and in September reported positive results from a mid-stage trial of its plaque psoriasis drug. Some Bristol-Myers investors are against the planned $74 billion (56 billion pounds) takeover of Celgene, as they see potential risk associated with Celgene’s pipeline, and expect a drop in sales of its flagship multiple myeloma drug, R
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies [Yahoo! Finance]Yahoo! Finance
- FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk [Seeking Alpha]Seeking Alpha
- Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb (NYSE: BMY) had its price target raised by analysts at Wells Fargo & Company from $51.00 to $52.00. They now have an "equal weight" rating on the stock.MarketBeat
- Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 2/2/24 - Beat
BMY
Sec Filings
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- BMY's page on the SEC website